Labcorp reaffirms 2026 outlook. Labcorp stock gains 1.09 percent.
Published on 10/06/2026 at 15:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Labcorp (ISIN US5049221055) was trading at EUR 277.00 at Lang & Schwarz on October 6, 2026 at 3:37 p.m. CEST, up 1.09 percent from the EUR 274.00 prior close. The company reaffirmed its full-year 2026 outlook on September 10, 2026, including revenue of USD 14.71 billion to USD 14.83 billion and adjusted earnings per share of USD 18.10 to USD 18.55, according to Labcorp.
Guidance points to higher earnings
The guidance sets a revenue growth range of 5.40 percent to 6.30 percent for 2026 and an adjusted earnings per share range of USD 18.10 to USD 18.55. Labcorp had raised the midpoint of its revenue guidance by USD 42 million and the adjusted earnings per share midpoint by USD 0.30 in its second-quarter update, according to Fortune.
The longer-term plan is more measured than the immediate 2026 earnings trajectory. Labcorp's September 10 release targets compound annual revenue growth of 5.00 percent to 8.00 percent through 2029 and adjusted earnings per share growth of 8.50 percent to 11.50 percent, according to Labcorp. That gap makes execution in diagnostics and biopharma services the central valuation question.
Quarterly growth has a cash counterweight
In the second quarter of 2026, revenue increased 5.80 percent year over year to USD 3.73 billion, while adjusted earnings per share rose 14.90 percent to USD 4.99. Adjusted operating margin expanded 70 basis points to 15.80 percent, and free cash flow was USD 314 million, according to Fortune.
Diagnostics revenue rose 5.50 percent to USD 2.90 billion in the quarter, while Biopharma Laboratory Services revenue increased 6.50 percent to USD 836 million. The cash figure was lower than the USD 543 million reported for the comparable quarter, according to Fortune. The contrast gives investors a concrete counterweight to the earnings growth.
NYSE range leaves room for volatility
On the NYSE, Labcorp was last quoted at USD 312.53 at 9:48 a.m. EDT on October 6, 2026. Its 52-week range was USD 244.52 to USD 341.80, and market capitalization stood at USD 25.6 billion on the same date.
Labcorp is scheduled to release third-quarter 2026 results before the market opens on October 28, 2026, with a webcast at 9:00 a.m. ET, according to Labcorp. That date is the next clear test of whether the raised 2026 assumptions are tracking ahead of the reporting cycle.
October trading keeps the catalyst visible
Lang & Schwarz showed Labcorp trading at EUR 277.00 on October 6, 2026 at 3:37 p.m. CEST, up 1.09 percent versus the EUR 274.00 prior close. The further course of trading is shown by the continuously updated real-time quote of Labcorp stock.
Labcorp stock at a glance
- Company: Labcorp Holdings Inc.
- ISIN: US5049221055
- Ticker: LH
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 6, 2026, 3:37 p.m. CEST): EUR 277.00
- Change versus prior close: plus 1.09 percent
- Prior close Lang & Schwarz (October 5, 2026): EUR 274.00
- Market capitalization: USD 25.6 billion (as of October 6, 2026)
- 52-week range: USD 244.52-341.80 (as of October 6, 2026)
- Sector / Industry: Healthcare / Diagnostics and Research
- Next earnings date: October 28, 2026
